RA0314

antibody from Oursmab

Targeting: IGF1 IGF, IGF-I, IGF1A, IGFI

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0314

Provider

Oursmab

Product name

Dusigitumab (Biosimilar Reference Antibody) (IGF1 and IGF2)

Antibody type

Monoclonal

Description

Dusigitumab (MEDI 573) is a human IgG2¦Ë monoclonal antibody developed as a targeted therapy for cancer. It is designed to neutralize the insulin-like growth factor (IGF) pathway by specifically binding to and inhibiting both IGF2 (Insulin-like Growth Factor 2) and IGF1 (Insulin-like Growth Factor 1). This dual-neutralization aims to block the activation of the IGF-1 receptor (IGF-1R) signaling axis, a key driver of tumor growth, survival, and resistance to therapy in various solid tumors. Clinical trials have evaluated its potential in malignancies where the IGF pathway is implicated, such as hepatocellular carcinoma and other advanced solid tumors.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Dusigitumab (Biosimilar Reference Antibody) (IGF1 and IGF2)-RA0314-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Dusigitumab (Biosimilar Reference Antibody) (IGF1 and IGF2)-RA0314 in a linear range of 15.63-500 ng/mL.